Food Allergy

Future studies of socioeconomic factors and environmental elements contributing may help to further explain the causes of food allergies and inform targeted interventions and management.

This new data indicates that the peanut patch was efficacious and safe in children with peanut allergies in this age bracket, expanding the body of research on desensitization for toddlers and young children.

New data on peanut allergy and Pediatric Quality of Life Inventory scores sheds light on the burden of allergy on adolescents.

In a recent letter to the editor, a newly-developed tool to assess one’s satisfaction with life when dealing with food allergy was introduced.

A recent study reviewed several educational interventions designed to promote food allergy literacy and knowledge for both parents and children.

Recent data, presented at the AAAAI annual meeting, showed that oral sesame desensitization through crushed seeds and tahini was efficacious and safe for pediatric patients.

Individuals with comorbid asthma, allergic rhinitis, and oral allergy syndrome had higher rates of eosinophilic esophagitis.

An interview featured Bird discussing data from his AAAAI annual meeting presentation on a new oral immunotherapy product for those with peanut allergies.

Late-breaking data presented by Dr. Christopher Warren indicates travelers with food allergy lack confidence in regulations and accommodations put in place for air travel.

"You want to be empowering children to be proactive and managing their medical condition in the healthiest, safest possible way," Dr. Christopher Warren said in an interview at AAAAI 2023.

Dr. Christopher Warren discusses the study he presented at AAAAI 2023 Annual Meeting that found 98% of participants experienced added anxiety when traveling due to their food allergy, with a "lamentingly high number" of negative experiences.

According to data from the AAAAI 2023 Annual Meeting, individuals with food allergies face numerous barriers when managing their condition while flying, with only 15% receiving epinephrine.

"We are looking at trying to satisfy a truly unmet medical need," Dr. David Dworaczyk says about the development of a new epinephrine nasal spray for anaphylaxis.

Dr. David Dworaczyk explains phase 3 data showing a single intranasal dose of epinephrine produced a higher and more prolonged plasma curve compared to an intramuscular 0.3 mg autoinjector.

Bryn Pharma CEO shares promising data on a novel intranasal epinephrine spray called Utuly during the AAAAI 2023 Annual Meeting.

New research into egg, peanut allergies and sensitization raised questions about allergy incidence rates and early exposure.

A literature review summarized research on sesame allergies as the FDA begins labeling sesame as a major food allergen.